Skip to content

Study on the safety and efficacy of Aurantii Fructus Immaturus flavonoid extract tablets (Aolanti) in the treatment of functional dyspepsia

A randomized, double-blind, placebo-controlled, multicenter clinical study on the safety and efficacy of Aurantii Fructus Immaturus flavonoid extract tablets (Aolanti) in the treatment of functional dyspepsia (liver-stomach disharmony, damp-heat in spleen and stomach, and food stagnation syndromes)

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
ISRCTN
Registry ID
ISRCTN32262691
Enrollment
270
Registered
2025-03-09
Start date
2010-03-01
Completion date
Unknown
Last updated
2025-03-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The treatment of patients with functional dyspepsia Digestive System

Interventions

The study adopted a multicenter, randomized, double-blind, placebo-parallel-controlled design, with stratification factors including study center and TCM syndrome type. The ratio of the treatment grou

Sponsors

Jiangxi Qingfeng Pharmaceutical Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Sign the informed consent form 2. Meet the Western medical diagnostic criteria for functional dyspepsia 3. Conform to the Traditional Chinese Medicine (TCM) syndrome diagnostic criteria for epigastric stuffiness (including liver-stomach disharmony, spleen-stomach damp-heat, and food stagnation syndromes) 4. Aged 18 to 65 years at the time of enrollment

Exclusion criteria

Exclusion criteria: 1. Individuals with organic diseases such as esophagitis, atrophic gastritis, gastric and duodenal ulcers, erosions, tumors, etc. 2. Individuals with organic diseases of the liver, gallbladder, or pancreas 3. Individuals with diabetes, kidney disease, connective tissue disease, or psychiatric disorders 4. Individuals with severe primary diseases of the heart, brain, lungs, kidneys, hematopoietic system, or endocrine system 5. Individuals with a history of abdominal surgery 6. Pregnant women, those with pregnancy intentions, or women who are breastfeeding 7. Individuals with mental or legal disabilities 8. Individuals who have participated in other drug clinical trials within the 3 months prior to this trial

Design outcomes

Primary

MeasureTime frame
Western Medicine Disease Efficacy: Using the Western medicine primary symptom grading and quantification standards, the four main symptoms are graded and scored, with each symptom corresponding to a score of 0-3. Assessments are conducted at the screening period, baseline, and on days 7, 14, 21, 28, and 56, with a focus on evaluating the efficacy based on the scores at day 28.

Secondary

MeasureTime frame
1. Traditional Chinese Medicine (TCM) Syndrome Efficacy: Using the TCM syndrome grading and quantification standards, patients with syndromes such as Liver-Stomach Disharmony, Spleen-Stomach Dampness-Heat, and Food Retention are scored based on their symptoms. Assessments are conducted at the screening period, baseline, and on days 7, 14, 21, 28, and 56, with a focus on evaluating the efficacy based on the scores at day 28. 2. Gastric Emptying Time: The barium strip method is used to measure the gastric emptying rate at 3.5 hours. Observations and recordings are conducted once before medication (baseline) and once after 28 days of medication. 3. Changes in Tongue and Pulse Manifestations: A comprehensive inquiry and physical examination are conducted to observe changes in tongue and pulse before, during, and after treatment. Tongue manifestations are primarily assessed through visual inspection, observing the color of the tongue body and the condition of the tongue coating. Pulse manifestations are primarily assessed through palpation, where the patient's pulse is evaluated to determine its characteristics.

Countries

China

Contacts

Public ContactTiancheng Qi
qitiancheng@qfyy.com.cn+86-18588477550

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026